Significance of soluble PD-L1 in melanoma patients [ 2015 - 2018 ]

Research Grant

Researchers: Prof Xu Dong Zhang (Principal investigator) ,  Dr Matteo Carlino ,  Prof Helen Rizos ,  Prof Patrick Mcelduff

Brief description A class of new immunotherapy drugs called “antibodies of immune checkpoints” can lead to long-lasting melanoma regression, but they are only beneficial to a subset of patients. This project will potentially identify the increased expression of a protein called PD-L1 in the blood as a biomarker predictive of responses of melanoma patients to these new drugs. The results will be instructive for selection of patients for the treatment.

Funding Amount $AUD 561,236.75

Funding Scheme Project Grants

Notes Standard Project Grant